Conditions: Major Depressive Disorder
Keywords: Depression Major Depressive Disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 442
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder

Detailed description:

Arms:
arm 1: Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. arm 2: Matching placebo capsules, oral administration, once daily dosing.

Interventions: intervention 1: Levomilnacipran ER intervention 2: Placebo
Intervention descriptions: intervention 1: Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks intervention 2: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.

Protocol document: